Metabolomics and its potential in drug development

Beyoglu, Diren; Idle, Jeffrey (2013). Metabolomics and its potential in drug development. Biochemical pharmacology, 85(1), pp. 12-20. Elsevier 10.1016/j.bcp.2012.08.013

[img] Text
Metabolomics and its potential in drug developmen.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (692kB) | Request a copy

Metabolomics is the global and unbiased survey of the complement of small molecules (say, <1 kDa) in a biofluid, tissue, organ or organism and measures the end-products of the cellular metabolism of both endogenous and exogenous substrates. Many drug candidates fail during Phase II and III clinical trials at an enormous cost to the pharmaceutical industry in terms of both time lost and of financial resources. The constantly evolving model of drug development now dictates that biomarkers should be employed in preclinical development for the early detection of likely-to-fail candidates. Biomarkers may also be useful in the preselection of patients and through the subclassification of diseases in clinical drug development. Here we show with examples how metabolomics can assist in the preclinical development phases of discovery, pharmacology, toxicology, and ADME. Although not yet established as a clinical trial patient prescreening procedure, metabolomics shows considerable promise in this regard. We can be certain that metabolomics will join genomics and transcriptomics in lubricating the wheels of clinical drug development in the near future.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Beyoglu, Diren and Idle, Jeffrey

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0006-2952

Publisher:

Elsevier

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

16 Jun 2014 16:57

Last Modified:

06 Nov 2015 09:52

Publisher DOI:

10.1016/j.bcp.2012.08.013

Uncontrolled Keywords:

Metabolomics, Drug development, Ultraperformance liquid chromatography–electrospray ionization-quadrupole time-of-flight mass spectrometry, Pharmacology, Toxicology

BORIS DOI:

10.7892/boris.53766

URI:

https://boris.unibe.ch/id/eprint/53766

Actions (login required)

Edit item Edit item
Provide Feedback